论文部分内容阅读
没有什么比专利更能牵动大药厂的神经,但从去年开始坏消息接踵而至。大药厂的明星产品专利相继到期,其在账单上贡献的年销售额几十亿美元一夜间蒸发。仿制药市场分秒必争,以合资方式深入渗透中国这个巨大的市场,能否真正抵御住另一种考验?目前仿制药在全球药品市场中的比重已从2000年的7%提高到15%左右,预测2015年将占据50%,而中国将在2015年会成为全球第二大医药市场。
Nothing can affect the nerve of a big pharmaceutical company more than a patent, but the bad news came one after the other last year. Major pharmaceutical product celebrity patents have matured, the bill contributed to the annual sales of billions of dollars evaporated overnight. Generic pharmaceutical market will be challenged by every second, penetrate deeply into China’s huge market with joint ventures, and can we truly withstand another test? At present, the proportion of generics in the global pharmaceutical market has risen from 7% in 2000 to about 15% 2015 will account for 50%, while China will become the world’s second largest pharmaceutical market in 2015.